Sex-Specific Differences in the Risk of Heart Failure following Anti-HER2 Monoclonal Antibody Therapy. Suzuki Y, Kaneko H, Tamura Y, Okada A, et al. Oncology 2023;101:358-361.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Suzuki Y, Kaneko H, Tamura Y, Okada A, et al. Sex-Specific Differences in the Risk of Heart Failure following Anti-HER2 Monoclonal Antibody Therapy. Oncology 2023;101:358-361.
PMID: 36940681